263 related articles for article (PubMed ID: 30458888)
1. Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Hu ZI; Hellmann MD; Wolchok JD; Vyas M; Shia J; Stadler ZK; Diaz LA; O'Reilly EM
J Immunother Cancer; 2018 Nov; 6(1):127. PubMed ID: 30458888
[TBL] [Abstract][Full Text] [Related]
2. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
[TBL] [Abstract][Full Text] [Related]
3. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
5. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Park H; Bang JH; Nam AR; Eun Park J; Hua Jin M; Bang YJ; Oh DY
Sci Rep; 2019 Jul; 9(1):11131. PubMed ID: 31366979
[TBL] [Abstract][Full Text] [Related]
7. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
[TBL] [Abstract][Full Text] [Related]
8. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
[TBL] [Abstract][Full Text] [Related]
9. Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Patil NR; Khan GN
Am J Case Rep; 2020 Jul; 21():e923803. PubMed ID: 32658872
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
[TBL] [Abstract][Full Text] [Related]
11. BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
Kondo T; Kanai M; Matsubara J; Quy PN; Fukuyama K; Yamamoto Y; Yamada T; Nishigaki M; Minamiguchi S; Takeda M; Nishio K; Matsumoto S; Muto M
Pancreas; 2020; 49(10):e101-e103. PubMed ID: 33017331
[No Abstract] [Full Text] [Related]
12. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
13. Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Ye Y; Zheng S
Front Immunol; 2021; 12():785400. PubMed ID: 34880877
[TBL] [Abstract][Full Text] [Related]
14. Response in
Campoverde LE; Batalini F; Bulushi Y; Bullock A
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
[TBL] [Abstract][Full Text] [Related]
15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
16. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
Hadj Bachir E; Poiraud C; Paget S; Stoup N; El Moghrabi S; Duchêne B; Jouy N; Bongiovanni A; Tardivel M; Weiswald LB; Vandepeutte M; Beugniez C; Escande F; Leteurtre E; ; Poulain L; Lagadec C; Pigny P; Jonckheere N; Renaud F; Truant S; Van Seuningen I; Vincent A
Biol Cell; 2022 Jan; 114(1):32-55. PubMed ID: 34561874
[TBL] [Abstract][Full Text] [Related]
17. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
18. Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review.
Zhu PF; Chen YW; Wang MX; Deng YY; Pan SY; Chen ZL; Yang L
Anticancer Drugs; 2022 Jan; 33(1):e822-e827. PubMed ID: 34459462
[TBL] [Abstract][Full Text] [Related]
19. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
Kubota Y; Han Q; Hozumi C; Masaki N; Yamamoto J; Aoki Y; Tsunoda T; Hoffman RM
Anticancer Res; 2022 May; 42(5):2567-2572. PubMed ID: 35489727
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
